iBio, Inc.

NASDAQ:IBIO

Biotechnology

Healthcare
$0.85 +0.00%

+$0.00 today

Market cap
$59.75M
Beta
1.29
P/E (TTM)
-3.6
EPS (TTM)
-$0.32
52W Low $0.78High $3.82

Volume 0.84M

Average 0.81M

IBIO Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

iBio, Inc.NASDAQ: IBIO

Accounts Payables · Q4 FY2026 · quarter ended Jun 2026

Accounts payables growth accelerates

Q4 FY2026 accounts payables of $1.38M rose 93.4% year over year, ahead of the +21.4% change in trailing-twelve-month accounts payables. Sequentially, it rose 262.4% from the prior quarter.

Context

  • Accounts payables amounted to 2223.0% of revenue in FY2026, up 1765.3 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +93.4% holds above the trailing-twelve-month pace of +21.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.38M+262.4% QoQ
Last fiscal yearJun 2026
$2.22M+21.4% YoY
LTMJun 2026
$2.22M+21.4% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+93.4%——
1 year+21.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2026
2.22M USD
Year-over-year change
+21.4%
4-year CAGR
+15.7%

Accounts Payables vs competitors

How IBIO compares with its peers on the latest reported figures

  • IBIO's LTM Jun 2026 accounts payables of $2.22M is the largest of the 4 companies compared; the peer median is $540K.
  • Its year-over-year change of +21.4% is the 3rd highest of 4, against a peer median of +158.8%.
  • Accounts payables amounts to 2223.0% of revenue for IBIO, versus a peer median of 62.9%.
IBIO Competitors Peer median
Accounts Payables for IBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IBIOiBio, Inc.LTM Jun 2026$2.22M +21.4%—2223.0%
BOLDBoundless Bio, Inc.LTM Mar 2026$646K +158.8%-5.1%—
RLYBRallybio CorporationLTM Mar 2026$540K +871.4%—62.9%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$457K -171.4%——
Peer median (excluding IBIO) $540K+158.8%-5.1%62.9%

Competitors are the stored peer set for IBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Net Income(29.51M)(65.01M)(24.91M)(18.38M)(33.04M)
Depreciation & Amortization3.79M1.38M1.25M291K88K
Deferred Income Tax00000
Stock-Based Compensation4.38M4.39M2.04M1.53M1.37M
Change in Working Capital3.24M5.87M(3.17M)479K2.52M
Accounts Receivables4.21M6.1M00(65K)
Inventory(3.87M)(1.02M)000
Accounts Payables1.24M(625K)(1.49M)1.83M2.22M
Other Working Capital1.66M1.41M(1.68M)(1.35M)364K
Other Non-Cash Items(15.32M)22.93M6.23M773K5.84M
Operating Cash Flow(37.8M)(30.44M)(18.55M)(15.3M)(23.22M)
Capital Expenditures(7.33M)(5.74M)(210K)(16K)(578K)
Acquisitions (Net)0(692K)000
Purchases of Investments(7.12M)000(42.3M)
Sales of Investments13.62M10.84M000
Other Investing Activities(4.3M)2.6M1.12M758K10.88M
Investing Cash Flow(5.13M)7.01M906K742K(32M)
Debt Repayment(5.83M)(9.13M)(1.14M)(771K)(6.63M)
Common Stock Issued77K11.49M25.52M9.7M109.58M
Common Stock Repurchased0(39K)(7K)00
Dividends Paid00000
Other Financing Activities(50K)(22K)197K0105K
Financing Cash Flow(5.8M)2.3M24.49M8.93M103.05M
Effect of Forex Changes(6M)33K00(18K)
Net Change in Cash(54.73M)(21.09M)6.85M(5.63M)47.83M
Free Cash Flow(45.13M)(36.17M)(18.76M)(15.32M)(23.8M)

iBio, Inc.

NASDAQ:IBIO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.